|
시장보고서
상품코드
2039052
메티실린 내성 황색포도상구균(MRSA) 치료제 시장 : 약제 클래스별, 유통 채널별, 지역별Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Drug Class, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
메티실린 내성 황색포도상구균(MRSA) 치료제 시장은 2026년에 12억 6,700만 달러로 추정되며, 2033년까지 17억 500만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR은 4.3%를 보일 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 12억 6,700만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR | 4.30% | 예측 금액(2033년) | 17억 500만 달러 |
메티실린 내성 황색포도상구균(MRSA)은 주로 병원이나 의료시설에서 발생하는 피부 감염입니다. 일반적으로 사용되는 항생제로 치료하지만, 보통 피부와 피부의 직접 접촉을 통해 사람에서 사람으로 감염됩니다. MRSA는 메티실린과 같은 일반적인 항생제에 내성을 보일 수 있기 때문에 의사들은 다른 대부분의 황색포도상구균 균주보다 치료가 더 어렵다고 느끼는 경우가 많습니다. MRSA 치료에 가장 일반적으로 사용되는 항생제에는 글리코펩타이드 및 리포글리코펩타이드, 옥사졸리디논, 리포펩타이드, 세팔로스포린 등이 있습니다. 이 약제들은 메티실린 내성 황색포도상구균의 감염을 사멸시키거나 억제하는 데 사용됩니다.
시장 역학
MRSA 감염 치료를 위한 파이프라인 제품 수 증가와 신제품 출시 및 승인 증가는 세계 메티실린 내성 황색포도상구균(MRSA) 시장의 성장을 이끄는 주요 요인 중 일부입니다. 예를 들어, 2018년 데스티니 파마(Destiny Pharma)는 메티실린 내성 황색포도상구균(MRSA) 수술 후 감염에 대응하기 위한 신규 후보물질인 2가 양이온성 포르피린 분자를 기반으로 한 비강용 겔 'XF-73'에 대해 FDA로부터 임상시험계획(IND) 승인을 받았습니다. 승인 받았습니다.
본 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 메티실린 내성 황색포도상구균(MRSA) 치료제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등 다양한 매개변수를 기반으로 정리하여 전해드립니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 메티실린 내성 황색포도상구균(MRSA) 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 메티실린 내성 황색포도상구균(MRSA) 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 메티실린 내성 황색포도상구균(MRSA) 치료제 시장 : 약제 클래스별(2021년-2033년)
제5장 세계의 메티실린 내성 황색포도상구균(MRSA) 치료제 시장 : 유통 채널별(2021년-2033년)
제6장 세계의 메티실린 내성 황색포도상구균(MRSA) 치료제 시장 : 지역별(2021년-2033년)
제7장 경쟁 구도
제8장 섹션
LSH 26.06.04Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market is estimated to be valued at USD 1,267 Mn in 2026 and is expected to reach USD 1,705 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,267 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.30% | 2033 Value Projection: | USD 1,705 Mn |
Methicillin-resistant staphylococcus aureus (MRSA) is an infection of the skin that occurs mostly in hospitals and healthcare facilities. It is treated with commonly used antibiotics and usually spreads from person to person by direct skin-to-skin contact. Physicians often find MRSA harder to treat than most other strains of staphylococcus aureus because it is sometimes resistant to commonly-used antibiotics such as methicillin. Some of the most commonly used antibiotics use for the treatment of MRSA include glycopeptides and lipoglycopeptides, oxazolidinones, lipopeptides, cephalosporin, and others. These drugs are used to kill or restrain Methicillin-resistant staphylococcus aureus infection.
Market Dynamics
Rising number of pipeline products, and increasing product launches & approval for the treatment of MRSA infection are some of the major factors responsible for the growth of global Methicillin-resistant staphylococcus aureus (MRSA) market. For instance, For instance, in 2018, Destiny Pharma received investigational new drug application from FDA for its new candidate, XF-73, a dicationic porphyrin molecule based nasal gel, to combat post-surgical infections of Methicillin-resistant Staphylococcus aureus (MRSA).
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc., Paratek Pharmaceuticals, Inc., Debiopharm International SA., Innovation Pharmaceuticals Inc., and Basilea Pharmaceutica Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Methicillin-resistant staphylococcus aureus (MRSA) drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Methicillin-resistant staphylococcus aureus (MRSA) drugs market
Market Segmentation
- By Drug Class Insights (Revenue, USD Mn, 2021 - 2033)
- Glycopeptides and Lipoglycopeptides
- Oxazolidinones
- Lipopeptides
- Cephalosporin
- Tetracycline
- Others
- By Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Merck & Co.Inc.
- Pfizer Inc.
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Melinta Therapeutics, Inc.
- Cumberland Pharmaceuticals Inc.
- Nabriva Therapeutics Plc.
- Paratek Pharmaceuticals, Inc.
- Debiopharm International SA.,
- Innovation Pharmaceuticals Inc.
- Basilea Pharmaceutica Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- CKD Stages Treatment Options
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Pipeline Analysis
- Market Trends
- Recent Product Launch/Approvals
- Cost of Treatment
- Regulatory Scenario
- PEST Analysis
- Mergers, Acquisitions, and Partnerships
- Epidemiology
- Brilacidin Effectiveness
- Brilacidin Research Perspective
- Reimbursement Scenario (Medicare Part D Spending)
4. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Drug Class, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Glycopeptides and Lipoglycopeptides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Oxazolidinones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Lipopeptides
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Tetracycline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
5. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Distribution Channel, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
6. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market, By Region, 2021 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- North America
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
7. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Melinta Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cumberland Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Nabriva Therapeutics Plc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Paratek Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Debiopharm International SA.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Innovation Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Basilea Pharmaceutica Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Analyst Views
- Merck & Co., Inc.
8. Section
- References
- Research Methodology
- About us and Sales Contact
